We further analyzed if other clinicopathologic factors can affect IDFS in HER2-positive BC patients managed with TCbHP-based dual-target NAT and found that, in addition to pCR, positive lymph node (HR, 2.523, 95% CI, 1.321-10.144; P=0.024) was also an independent prognostic factor for IDFS, which was consistent with previous findings reported by the NSABP B-18 and B-27 studies (29, 30). Here, ERBB2 is linked to breast cancer.